DBV's peanut allergy patch is finally under FDA review; Ritter swallows bitter pill to explore strategic alternatives
→ DBV Technologies $DBVT, which withdrew its application to market its peanut allergy patch late last year, essentially enabling rival Aimmune $AIMT to leapfrog it, on Friday announced that the FDA has accepted its latest BLA filing. The agency is expected to make its decision by August 5 — but will host an advisory panel meeting to discuss the immunotherapy.
→ Ritter Pharmaceuticals $RTTR did its best to make lemonade with the lemons it was dealt — by vaulting its lactose intolerance therapy toward a confirmatory trial, despite missing the main goal in the preceding Phase II/III study. Last month, the company reported its therapy, RP-G28, failed not only to secure a statistically significant improvement versus placebo in reducing lactose intolerance symptoms, but patients in the placebo group actually did better than the drug arm. Now, the LA-based company has appointed a financial advisor to explore strategic alternatives.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.